



Table with 6 columns: CLIENT / BRAND, BATCH ID, CLIENT BATCH / LOT, COMPOUND, SAMPLE (AS RUN), DATE RECEIVED. Data includes Thryve Research, TR-20260907-D5HF, THR-IPA10-01, Ipamorelin, TR-20260907-D5HF-01, and 07 SEP 2026.

DATE ANALYZED
19 SEP 2026


Table with 3 columns: CHROMATOGRAPHIC PURITY (99.98%), CONTENT PER VIAL (10.32), RETENTION TIME (1.020). Includes sub-labels like MG PER VIAL, LABEL CLAIM, and SPEC.

Overall: Conforms to specification — Identity Conforms (RT + UV vs. reference); sample meets the acceptance criteria below.
SPEC SET IS CLIENT / METHOD-DEFINED

SUMMARY OF RESULTS

Table with 4 columns: TEST, SPECIFICATION, RESULT, STATUS. Rows include Appearance, Purity (HPLC, area %), and Content (mg/vial).

CHROMATOGRAM & SAMPLE REFERENCE



How to read this. Chromatographic purity is the percentage of total integrated peak area — how much of the detected material is the target peptide versus impurities. It is not a measure of net peptide mass content (what fraction of the powder is peptide versus counter-ion, water, or residual solvent). That mass content is measured separately and reported above as content per vial (mg net peptide). Results apply only to the sample submitted.

AUTHORIZED SIGNATORY · KMD ANALYTICAL
Kevin Doud
Laboratory Director

DATE OF ISSUE
19 SEP 2026

KMD Analytical (KMD Group LLC) is an independent third-party analytical testing laboratory. The results reported herein were produced by KMD Analytical using validated HPLC-DAD methodology on file with the laboratory and apply solely to the specific sample as received from the client; they do not necessarily represent other units, lots, or production runs.

This certificate reports analytical findings on the submitted sample only. It is not a determination of safety or fitness for any use, and does not evaluate the client's manufacturing or sourcing. KMD Analytical is not FDA-registered and does not perform GMP release testing. Scope: kmdanalytical.com/scope